Determination of the distribution of light, optical properties, drug concentration, and tissue oxygenation in-vivo in human prostate during motexafin lutetium-mediated photodynamic therapy.
暂无分享,去创建一个
[1] M Saunders,et al. Photodynamic therapy in the canine prostate using motexafin lutetium. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[2] C. Whitehurst,et al. In vivo laser light distribution in human prostatic carcinoma. , 1994, The Journal of urology.
[3] Rex Cheung,et al. In vivo reflectance measurement of optical properties, blood oxygenation and motexafin lutetium uptake in canine large bowels, kidneys and prostates. , 2002, Physics in medicine and biology.
[4] A. D'Amico,et al. Role of interstitial radiotherapy in the management of clinically organ-confined prostate cancer: the jury is still out. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] B. Wilson,et al. Preclinical Studies in Normal Canine Prostate of a Novel Palladium‐Bacteriopheophorbide (WST09) Photosensitizer for Photodynamic Therapy of Prostate Cancer ¶ , 2002 .
[6] Jarod C Finlay,et al. In vivo determination of the absorption and scattering spectra of the human prostate during photodynamic therapy , 2004, SPIE BiOS.
[7] A. Raffle. Trust me, I'm a scientist: will urologists set a lead for geneticists to follow? , 1996, The Lancet.
[8] Alicia Samuels,et al. Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.
[9] Zheng Huang,et al. Preclinical Studies in Normal Canine Prostate of a Novel Palladium-Bacteriopheophorbide (WST09) Photosensitizer for Photodynamic Therapy of Prostate Cancer¶ , 2002, Photochemistry and photobiology.
[10] F. Hetzel,et al. Interstitial photodynamic therapy in the canine prostate. , 1997, British journal of urology.
[11] Jonathan L. Sessler,et al. Texaphyrins: Synthesis and Development of a Novel Class of Therapeutic Agents , 2002 .
[12] Timothy C Zhu,et al. In vivo Optical Properties of Normal Canine Prostate at 732 nm Using Motexafin Lutetium–mediated Photodynamic Therapy¶ , 2003, Photochemistry and photobiology.
[13] Mamoru Tamura,et al. Expression of optical diffusion coefficient in high-absorption turbid media , 1997 .
[14] S. Jacques,et al. Light Distributions from Point, Line and Plane Sources for Photochemical Reactions and Fluorescence in Turbid Biological Tissues , 1998, Photochemistry and photobiology.
[15] Timothy C. Zhu,et al. Phase I trial of motexafin-lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer , 2004, SPIE BiOS.
[16] R. Steiner,et al. Spatially resolved absolute diffuse reflectance measurements for noninvasive determination of the optical scattering and absorption coefficients of biological tissue. , 1996, Applied optics.
[17] M R Arnfield,et al. OPTICAL PROPERTIES OF EXPERIMENTAL PROSTATE TUMORS in vivo , 1993, Photochemistry and photobiology.
[18] Michael S Patterson,et al. Quantification of fluorophore concentration in tissue-simulating media by fluorescence measurements with a single optical fiber. , 2003, Applied optics.
[19] M. Tamura,et al. Expression of optical diffusion coefficient in high-absorption turbid media. , 1998, Physics in medicine and biology.
[20] C. Whitehurst,et al. Photodynamic therapy for localised prostatic cancer: light penetration in the human prostate gland. , 1990, The Journal of urology.
[21] R. Doornbos,et al. The determination of in vivo human tissue optical properties and absolute chromophore concentrations using spatially resolved steady-state diffuse reflectance spectroscopy. , 1999, Physics in medicine and biology.
[22] R. Keck,et al. Transperineal photodynamic ablation of the canine prostate. , 1996, The Journal of urology.
[23] L. K. Lee,et al. In situ COMPARISON OF 665 nm and 633 nm WAVELENGTH LIGHT PENETRATION IN THE HUMAN PROSTATE GLAND , 1995, Photochemistry and photobiology.
[24] W. Star,et al. Calibration of isotropic light dosimetry probes based on scattering bulbs in clear media. , 1996, Physics in medicine and biology.
[25] D. Kessel,et al. Localization and Efficacy Analysis of the Phototherapeutic Lutetium Texaphyrin (PCI‐0123) in the Murine EMT6 Sarcoma Model , 1997, Photochemistry and photobiology.
[26] Rainer Storn,et al. Differential Evolution – A Simple and Efficient Heuristic for global Optimization over Continuous Spaces , 1997, J. Glob. Optim..
[27] T. Dougherty. Photodynamic therapy. , 1993, Photochemistry and photobiology.
[28] Shi-Chung Chang,et al. Interstitial and transurethral photodynamic therapy of the canine prostate using meso‐tetra‐(m‐hydroxyphenyl) chlorin , 1996, International journal of cancer.
[29] J. Sessler,et al. Lutetium Texaphyrin (PCI‐0123): A Near‐Infrared, Water‐Soluble Photosensitizer , 1996, Photochemistry and photobiology.
[30] T C Zhu,et al. Modeling the output ratio in air for megavoltage photon beams. , 2001, Medical physics.
[31] B. Wilson,et al. Changes in in vivo optical properties and light distributions in normal canine prostate during photodynamic therapy. , 1997, Radiation research.
[32] Shi‐Chung Chang,et al. Interstitial photodynamic therapy in the canine prostate with disulfonated aluminum phthalocyanine and 5‐aminolevulinic acid‐induced protoporphyrin IX , 1997, The Prostate.
[33] L. Murrer,et al. Photodynamic therapy as adjuvant therapy in surgically treated pleural malignancies. , 1997, British Journal of Cancer.
[34] Stephen G Bown,et al. Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase I study. , 2002, The Journal of urology.
[35] Timothy C. Zhu,et al. Optical Properties of Human Prostate at 732 nm Measured In Vivo During Motexafin Lutetium–mediated Photodynamic Therapy¶ , 2005 .
[36] M. Stromborg. Screening For Early Detection , 1981, The American journal of nursing.
[37] E. Hull,et al. Porphyrin Bleaching and PDT-induced Spectral Changes are Irradiance Dependent in ALA-sensitized Normal Rat Skin In Vivo¶ , 2001, Photochemistry and photobiology.